Table 3.
Biomarker (High vs. Low) |
Nodal Status (N2 vs. N1) |
Vascular Invasion (Y vs. N) |
||||
---|---|---|---|---|---|---|
HR (95% CI) | p | HR (95%CI) | p | HR (95%CI) | p | |
A. Disease-Free Survival in the Institutional Cohort | ||||||
by PT-TAMsb | 0.23 (0.08–0.65) | 0.005 | 2.43 (1.34–4.42) | 0.001 | 2.02 (1.11–3.68) | 0.02 |
by LN-TAMsb | 0.13 (0.04–0.43) | 0.001 | 2.35 (1.19–4.63) | 0.01 | 2.36 (1.21–4.62) | 0.01 |
by TANsc | 0.53 (0.22–1.30) | 0.17 | 2.47 (1.31–4.67) | 0.005 | 2.29 (1.22–4.30) | 0.01 |
B. Disease-Specific Survival in the External Validation Set | ||||||
by PT-TAMsb | 0.14 (0.02–1.00) | 0.05 | 2.54 (1.09–5.90) | 0.03 | 1.57 (0.58–4.21) | 0.37 |
Distinct models were constructed to weight the predictive value of each candidate biomarker. Only variables with a p value less than 0.10 at univariate analysis (see Table 3) were entered.
percent CD68-immunoreactive area (IRA) at the invasive front of the primary tumor (PT-TAMs) or of metastatic lymph nodes (LN-TAMs). Low vs. high densities are defined by optimal cut-offs from Receiver Operator Characteristic curves (8.0% IRA for PT-TAMS and 3.7% IRA for LN-TAMs)
percent CD66b-immunoreactive (IRA) within the primary tumor (TANs). Low vs. high densities are defined by optimal cut-offs from Receiver Operator Characteristic curves (1.16% IRA )